摘要
目的评价国产多西他赛联合奥沙利铂作为铂类耐药的晚期卵巢上皮癌解救化疗的疗效和毒性。方法23例经肿瘤细胞减灭术及铂类药物化疗耐药的晚期卵巢癌患者,采用国产多西他赛联合奥沙利铂化疗,即第1天给予多西他赛70mg/m2静脉滴注,第2天给予奥沙利铂130mg/m2静脉滴注。每3周为1周期,重复给药共112个周期。结果23例中完全缓解1例,部分缓解6例,无变化7例,病情进展9例,总有效率30.4%。Ⅲ、Ⅳ度白细胞下降为17.4%,Ⅲ度血红蛋白下降为4.3%,Ⅲ度疲乏为4.3%。其他不良反应轻微。结论国产多西他赛联合奥沙利铂治疗铂类耐药的晚期卵巢上皮癌疗效满意,不良反应少,值得深入研究。
Objective To evaluate the efficacy and toxicity of docetaxel plus oxaliplatin in the treatment of platinum resistance advanced epithelia ovary cancer. Methods 23 cases of advanced epithelia ovary cancer pretreated with cytoreductive surgery and platinum resistance received the salvage treatment. Docetaxel 70mg/m^2 i. v at the first day combined with oxaliplatin 130 mg/m^2 i. v at the second day was given to the patients on the first day of chemotherapy. The regimen was given per 3 weeks, altogether 112 cycles. Results Complete relief was obtained in 1 case, partial relief in 6 cases, no change in 7 cases, and progression in 9 cases, with an overall response rate of 30. 4%. The main side effect included grade Sand Ⅳ leukopenia （ 17.4% ） ,grade Ⅲ anemia （4.3%） ,and grade Ⅲ asthenia （4.3%）. Other adverse effects were slight. Conclusion Docetaxel plus oxaliplatin is effective in treating platinum resistance advanced epithelia ovary cancer, with slight adverse effects.
出处
《中国综合临床》
北大核心
2006年第7期656-658,共3页
Clinical Medicine of China
